Key Takeaways FDA lifts clinical hold on NTLA's MAGNITUDE-2 phase III IND for nex-z in ATTRv-PN, enabling study resumption.NTLA aligned with the FDA on study changes and liver monitoring. It plans to resume enrollment and dosing.Nex-z is Intellia's lead program, in partnership with Regeneron, which shares 25% of R&D costs and profits.Intellia Therapeutics (NTLA) announced that the FDA lifted the clinical hold on the investigational new drug application (IND) for the phase III study, MAGNITUDE-2, evaluating ...